Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AGA-2115 by Angitia Biopharmaceuticals for Osteogenesis Imperfecta: Likelihood of Approval
AGA-2115 is under clinical development by Angitia Biopharmaceuticals and currently in Phase I for Osteogenesis Imperfecta. According to GlobalData, Phase...